TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PYC Therapeutics Limited ( (AU:PYC) ) has shared an update.
PYC Therapeutics Limited announced the results of its Annual General Meeting, where Resolutions 1 and 3 were passed, while Resolution 2 was withdrawn. The approval of these resolutions reflects the company’s ongoing governance and strategic direction, potentially impacting its operations and industry positioning.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. The company leverages a proprietary drug delivery platform to enhance the effectiveness of precision medicines, particularly targeting monogenic diseases, which have a higher likelihood of success in clinical development.
Average Trading Volume: 702,200
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$799.1M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.